Published on 10 Mar 2024 on Simply Wall St. via Yahoo Finance
US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These...
Poseida Therapeutics, Inc. (NASDAQ:PSTX) just released its latest full-year results and things are looking bullish. Revenues of US$65m beat estimates by a substantial 40% margin. Unfortunately, Poseida Therapeutics also reported a statutory loss of US$1.37 per share, which at least was smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for Poseida Therapeutics
